Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: A multicenter, randomized, crossover study

Diabetes Technology and Therapeutics

Volumn 13, Issue 12, 2011, Pages 1213-1218

  Renard, Eric ^a,d   Dubois Laforgue, Danièle ^b   Guerci, Bruno ^c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Cochin Hospital ^*  (France)

^c Ctr Hospitalier Univ de Nancy   (France)

^d LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 82455164361     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0063     Document Type: Article

References (23)

1. Heinemann L: Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682. (Pubitemid 35283332)
2. Guerci B, Sauvanet JP: Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 2005; 31:4S7-4S24. (Pubitemid 41379375)
3. Gin H, Hanaire-Broutin H: Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005;31:7-13. (Pubitemid 40327587)
4. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295: 1681-1687.
5. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes Care 2005;54:1615-1625. (Pubitemid 40770750)
6. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-1834.
7. Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110: 214-219. (Pubitemid 38924590)
8. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E: The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171-175. (Pubitemid 38221817)
9. Weber C, Schnell O: The assessment of glycemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 2009;11:623-633.
10. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
11. Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008;31:2198-2202.
12. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in Type 1 diabetes. Diabetes Care 2006;29:1486-1490. (Pubitemid 44127568)
13. Gerich J, Becker RHA, Zhu R, Bolli GB: Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 2006;8:237-243. (Pubitemid 43848044)
14. White NH, Chase HP, Arslanian S, Tamborlane WV, for the 4030 Study Group: Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 2009;32:387-393.
15. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C: Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis 2009;19:571-579.
16. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-1671.
17. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JWF, Haahr H, Kristensen A, Draeger E: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;25:590-596. (Pubitemid 36929312)
18. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin. Diabetes Care 2001;24:296-301.
19. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G: Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-625.
20. Heise T, Nosek L, Rnn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53: 1614-1620. (Pubitemid 38697678)
21. Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI: Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007;24: 635-642. (Pubitemid 46808860)
22. Heller S, Koenen C, Bode B: Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with Type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009;31:2086-2097.
23. Reach G: Continuous glucose monitoring and diabetes health outcomes: a critical appraisal. Diabetes Technol Ther 2008;10:69-80. (Pubitemid 351230288)